Fulltext

Foscarnet Decreases Human Immunodeficiency Virus RNA

Kaiser, Laurent ; Perrin, Luc ; Hirschel, Bernard ; Furrer, Hansjakob ; Von Overbeck, Jan ; Olmari, Maya ; Yerly, Sabine

In: Journal of Infectious Diseases, 1995, vol. 172, no. 1, p. 225-227

Ajouter à la liste personnelle
    Titre
    • Foscarnet Decreases Human Immunodeficiency Virus RNA
    Auteur
    • Kaiser, Laurent. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Perrin, Luc. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Hirschel, Bernard. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Furrer, Hansjakob. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Von Overbeck, Jan. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Olmari, Maya. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    • Yerly, Sabine. Division of Infectious Diseases, Central Laboratory of Virology, University Hospital, Geneva, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Infectious Diseases, 1995, vol. 172, no. 1, p. 225-227. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:293914
    Summary
    Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis. To evaluate the effect of foscarnet on HIV replication, HIV RNA was quantitated in 17 patients before and during foscarnet therapy. Fifteen patients had CMV retinitis, 1 had CMV encephalitis, and 1 had intractable zoster. A decrease in HIV RNA was observed in 16 of 17 patients. Before the introduction of foscarnet, mean HIV RNA was 5.82 ± 0.24 log RNA/mL and, after a median of 13 days of therapy, mean HIV RNA was 5.30 ± 0.27 log RNA/mL (P < .001). Among patients with detectable p24 antigen at baseline, a significant decrease was observed (P = .017). This decrease in HIV RNA demonstrates that foscarnet is a potent antiretroviral drug